Lumera said it will combine Helix Biopharma's Heterodimer Protein Technology with its own NanoCapture Array technology. The integrated technologies will allow Lumera to produce and capture proteins on a silicon surface while keeping the proteins fully functional, the company said.
Financial terms of the agreement were not provided.
The company said it has already produced prototype chips using the combined technologies, and carried out enzymatic, binding, and proteomic studies.
Lumera said it plans to begin shipping a product based on the technology later this year.